“At $2 a share, PDL was ignored. At $98.50 most folks kicked themselves.”
Imagine earning
48.4 times
your money…
PDL Biopharm discovers and develops therapies for life-threatening illnesses, including high blood pressure, heart ailments, cancer, asthma among others. For years, the stock was practically flat, going no where. Then they were “discovered” and the years of research paid off. Next stop: almost $100 a share from $2.
PDL BioPharma is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Visit PDLI website. | | |
| The best investors are long: Top 100 Everyone Else | |
No comments:
Post a Comment